Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q2 EPS of $0.30, $0.07 better than the analyst estimate of $0.23. Revenue for the quarter came in at $796.2 million versus the consensus estimate of $758.24 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2026 EPS of $0.96-$1.06, versus the consensus of $0.98. Amneal Pharmaceuticals sees FY2026 revenue of $3.1-3.2 billion, versus the consensus of $3.12 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.